Crizotinib is an effective c-Met and ALK inhibitor and is considered the first-line drug for the treatment of advanced NSCLC with an ALK gene mutation (Jaboin et al., 2002; Shaw et al., 2020). This evidence concerns the gene ALK and non-small cell lung carcinoma.